EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Influence of concomitant distant lymph node metastases in metastatic hormone-sensitive prostate cancer patients with bone metastases

Mike Wenzel, Benedikt Lauer, Vincenzo Giuseppe Mühlthaler, Maximilian Filzmayer, Carolin Siech, Chi Le, Clara Humke, Marina Kosiba, Maximilian Kriegmair, Thomas Steuber, Felix K H Chun, Philipp Mandel

World Journal of Urology · 24.03.2026 · 44 (1)

DOI: 10.1007/s00345-026-06358-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift World Journal of Urology, online erschienen am 24.03.2026. Verfasst von Mike Wenzel und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany. Hauptthemen laut MEDLINE: Bone Neoplasms, Lymphatic Metastasis, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Johann Wolfgang Goethe-Universität, Frankfurt am Main.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Most patients with metastatic hormone-sensitive prostate cancer (mHSPC) are burdened by bone metastases. However, the impact of concomitant distant lymph node metastases at diagnosis in these patients is unknown. Materials and methods We relied on a single-center retrospective mHSPC patient cohort treated between 2014 and 2024 to compare time to metastatic castration-resistant prostate cancer (mCRPC) and overall survival (OS) between M1b vs. M1a + b mHSPC patients. Univariable and multivariable Cox regression models were applied.

Results

Among 432 patients, 64% harbored M1b vs. 36% M1a + b mHSPC. Median PSA was numerically higher (82 vs. 46 ng/ml, p = 0.2) and rates of LATITUDE high-risk (76% vs. 55%) and CHAARTED high-volume disease (70% vs. 50%) were significantly higher in the M1a + b group (both p < 0.001). Regarding time to mCRPC, median time to CRPC was 26 vs. 16 months for M1b vs. M1a + b patients (hazard ratio [HR]: 1.6, p < 0.01). Regarding OS, median OS was not significantly different, with median OS of 53 vs. 47 months for M1b vs. M1a + b patients ( p = 0.9). After controlling for patient and tumor characteristics in multivariable Cox regression analyses, concomitant lymph node metastases were not an independent risk for shorter time to CRPC or OS in patients with bone metastases (both p > 0.15).

Conclusion

Patients with concomitant distant lymph node metastases in mHSPC with bone metastases (M1a + b) harbor more unfavorable baseline cancer characteristics relative to M1b without lymph node metastases, translating into significantly shorter time to mCRPC. However, after controlling for patient and tumor characteristics, neither time to mCRPC nor OS seems not be affected by concomitant lymph node metastases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bone NeoplasmsLymphatic MetastasisProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantHumansMaleRetrospective StudiesAgedMiddle AgedSurvival Rate

Stichwörter der Autor:innen

Bone metastasesLymph node metastasesMetastatic burdenMetastatic hormone-sensitive prostate cancerProstate cancerSurvival ratemHSPC

Autor:innen und Institutionen

  • Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany.
  • Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany. Benedikt.Lauer@unimedizin-ffm.de.
  • Urologische Klinik München Planegg, Planegg, Germany.
  • Department of Urology and Urosurgery, Medical Faculty Mannheim, University Medical Center Mannheim, Heidelberg University, Mannheim, Germany.
  • Martini-Klinik Prostate Cancer Center, Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.

Förderung

  • Johann Wolfgang Goethe-Universität, Frankfurt am Main

Zitieren

APA

Wenzel, M., Lauer, B., Mühlthaler, V. G., Filzmayer, M., Siech, C., Le, C., Humke, C., Kosiba, M., Kriegmair, M., Steuber, T., Chun, F. K. H., & Mandel, P. (2026). Influence of concomitant distant lymph node metastases in metastatic hormone-sensitive prostate cancer patients with bone metastases. World Journal of Urology, 44(1). https://doi.org/10.1007/s00345-026-06358-5

Vancouver

Wenzel M, Lauer B, Mühlthaler VG, Filzmayer M, Siech C, Le C, et al. Influence of concomitant distant lymph node metastases in metastatic hormone-sensitive prostate cancer patients with bone metastases. World Journal of Urology. 2026;44(1). doi:10.1007/s00345-026-06358-5

BibTeX
@article{Wenzel2026,
  author = {Wenzel, Mike and Lauer, Benedikt and Mühlthaler, Vincenzo Giuseppe and Filzmayer, Maximilian and Siech, Carolin and Le, Chi and Humke, Clara and Kosiba, Marina and Kriegmair, Maximilian and Steuber, Thomas and Chun, Felix K H and Mandel, Philipp},
  title = {Influence of concomitant distant lymph node metastases in metastatic hormone-sensitive prostate cancer patients with bone metastases},
  journal = {World Journal of Urology},
  year = {2026},
  volume = {44},
  number = {1},
  doi = {10.1007/s00345-026-06358-5}
}
Kostenlos starten →